Loss of bone and Wnt10b expression in male type 1 diabetic mice is blocked by the probiotic Lactobacillus reuteri

Endocrinology (United States)

Volumn 156, Issue 9, 2015, Pages 3169-3182

  Zhang, Jing ^a,d   Motyl, Katherine J ^a   Irwin, Regina ^a   MacDougald, Ormond A ^a   Britton, Robert A ^b   McCabe, Laura R ^a,c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Michigan State University ^*  (United States)

^c St John Hospital and Medical Center   (United States)

^d XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; WNT10B PROTEIN; WNT PROTEIN; WNT10B PROTEIN, MOUSE;

ADIPOCYTE; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MARROW CELL; BONE MARROW STROMA CELL; BONE MASS; BONE MINERAL; BONE REMODELING; CONTROLLED STUDY; CORTICAL BONE; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LACTOBACILLUS REUTERI; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; MUSCLE MASS; NONHUMAN; OBESITY; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRABECULAR BONE; ANIMAL; C57BL MOUSE; COMPLICATION; DRUG EFFECTS; METABOLISM; TRANSGENIC MOUSE;

ANIMALS; DIABETES MELLITUS, TYPE 1; LACTOBACILLUS REUTERI; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; OSTEOBLASTS; OSTEOPOROSIS; PROBIOTICS; WNT PROTEINS;

EID: 84942787029     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/EN.2015-1308     Document Type: Article

References (75)

1. Sabin MA, Cameron FJ, Werther GA Type 1 diabetes-still the commonest form of diabetes in children. Aust Fam Physician. 2009; 38:695-697.
2. Kayal RA, Tsatsas D, Bauer M.A., et al. Diminished bone formation during diabetic fracture healing is related to the premature resorption of cartilage associated with increased osteoclast activity. J Bone Miner Res. 2007; 22:560-568.
3. Alblowi J, Kayal RA, Siqueira M, et al High levels of tumor necrosis factor-α contribute to accelerated loss of cartilage in diabetic fracture healing. Am J Pathol. 2009; 175:1574-1585.
4. Danne T, Kordonouri O, Enders I., Weber B. Factors influencing height and weight development in children with diabetes. Results of the Berlin Retinopathy Study. Diabetes Care. 1997; 20:281-285.
5. Holl RW, Grabert M, Heinze E., Sorgo W, Debatin KM. Age at onset and long-term metabolic control affect height in type-1 diabetes mellitus. Eur J Pediatr. 1998; 157:972-977.
6. Hinoi E, Gao N, Jung D.Y., et al. An osteoblast-dependent mechanism contributes to the leptin regulation of insulin secretion. Ann NY Acad Sci. 2009; 1173(Suppl 1):E20-E30.
7. Yoshizawa T, Hinoi E, Jung D.Y., et al. The transcription factor ATF4 regulates glucose metabolism in mice through its expression in osteoblasts. J Clin Invest. 2009; 119:2807-2817.
8. Martin LM, McCabe LR Type I diabetic bone phenotype is location but not gender dependent. Histochem Cell Biol. 2007; 128:125-133.
9. Zhang J, Coe L, Motyl K.J., McCabe L. Mouse strain dependent and independent effects of type 1 diabetic bone pathology. Diabetes Metab. 2012; S1-008.
10. Botolin S, McCabe LR Bone loss and increased bone adiposity in spontaneous and pharmacologically induced diabetic mice. Endocrinology. 2007; 148:198-205.
11. +/- and streptozotocin-induced type I diabetes cause bone loss in young mice. J Cell Physiol. 2013; 228:689-695.
12. Schwartz AV, Sellmeyer DE Diabetes, fracture, and bone fragility. Curr Osteoporos Rep. 2007; 5:105-111.
13. McCabe L, Zhang J, Raehtz S. Understanding the skeletal pathology of type 1 and 2 diabetes mellitus. Crit Rev Eukaryot Gene Expr. 21:187-206.
14. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005; 54:1615-1625.
15. McCabe LR. Understanding the pathology and mechanisms of type I diabetic bone loss. J Cell Biochem. 2007; 102:1343-1357.
16. Botolin S, McCabe LR Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem. 2006; 99:411-424.
17. Motyl KJ, Botolin S, Irwin R., et al. Bone inflammation and altered gene expression with type I diabetes early onset. J Cell Physiol. 2009; 218:575-583.
18. Coe LM, Irwin R, Lippner D., McCabe LR. The bone marrow microenvironment contributes to type I diabetes induced osteoblast death. J Cell Physiol. 2011; 226:477-483.
19. Kayal RA, Siqueira M, Alblowi J., et al. TNF-α mediates diabetesenhanced chondrocyte apoptosis during fracture healing and stimulates chondrocyte apoptosis through FOXO1. J Bone Miner Res. 2010; 25:1604-1615.
20. Ko KI, Coimbra LS, Tian C, et al Diabetes reduces mesenchymal stem cells in fracture healing through a TNFα-mediated mechanism. Diabetologia. 2015; 58:633-642.
21. Botolin S, Faugere MC, Malluche H, Orth M., Meyer R, McCabe LR. Increased bone adiposity and peroxisomal proliferator-activated receptor-72 expression in type I diabetic mice. Endocrinology. 2005; 146:3622-3631.
22. Moon RT. Wnt/β-catenin pathway. Sci STKE. 2005; 2005:cm1.
23. Baron R, Rawadi G. Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007; 148:2635-2643.
24. Bennett CN, Ross SE, Longo K.A., et al. Regulation of Wnt signaling during adipogenesis. J Biol Chem. 2002; 277:30998-31004.
25. Ross SE, Hemati N, Longo K.A., et al. Inhibition of adipogenesis by Wnt signaling. Science. 2000; 289:950-953.
26. Ross SE, Erickson RL, Gerin I, et al Microarray analyses during adipogenesis: understanding the effects of Wnt signaling on adipogenesis and the roles of liver X receptor α in adipocyte metabolism. Mol Cell Biol. 2002; 22:5989-5999.
27. Kang S, Bennett CN, Gerin I, et al Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT / enhancer-binding protein α and peroxisome proliferator-activated receptory. J Biol Chem. 2007; 282:14515-14524.
28. Kubota T, Michigami T, Ozono K. Wnt signaling in bone metabolism. J Bone Miner Metab. 2009; 27:265-271.
29. Bennett CN, Ouyang H, Ma Y.L., et al. Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation. J Bone Miner Res. 2007; 22:1924-1932.
30. Bennett CN, Longo KA, Wright W.S., et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA. 2005; 102:3324-3329.
31. Gilbert LC, Chen H, Lu X., Nanes MS. Chronic low dose tumor necrosis factor-α (TNF) suppresses early bone accrual in young mice by inhibiting osteoblasts without affecting osteoclasts. Bone. 2013; 56:174-183.
32. Shornikova AV, Casas IA, Isolauri E, Mykkänen H, Vesikari T. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J Pediatr Gastroenterol Nutr. 1997; 24:399-404.
33. Shornikova AV, Casas IA, Mykkänen H, Salo E., Vesikari T. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J. 1997; 16:1103-1107.
34. Frese SA, Hutkins RW, Walter J. Comparison of the Colonization ability of autochthonous and allochthonous strains of lactobacilli in the human gastrointestinal tract. Adv Microbiol. 2012; 2:399-409.
35. Oh PL, Benson AK, Peterson D.A., et al. Diversification of the gut symbiont Lactobacillus reuteri as a result of host-driven evolution. ISME J. 2010; 4:377-387.
36. Thomas CM, Hong T, van Pijkeren JP, et al. Histamine derived from probiotic Lactobacillus reuteri suppresses TNF via modulation of PKA and ERK signaling. PLOS One. 2012; 7:e31951.
37. Schaefer L, Auchtung TA, Hermans K.E., Whitehead D., Borhan B, Britton RA. The antimicrobial compound reuterin (3-hydroxypropionaldehyde) induces oxidative stress via interaction with thiol groups. Microbiology. 2010; 156:1589-1599.
38. McCabe LR, Irwin R, Schaefer L., Britton RA. Probiotic use decreases intestinal inflammation and increases bone density in healthy male but not female mice. J Cell Physiol. 2013; 228:1793-1798.
39. Britton RA, Irwin R, Quach D., et al. Probiotic L. reuteri treatment prevents bone loss in a menopausal ovariectomized mouse model. J Cell Physiol. 2014; 229:1822-1830.
40. Motyl KJ, McCauley LK, McCabe LR Amelioration of type I diabetes-induced osteoporosis by parathyroid hormone is associated with improved osteoblast survival. J Cell Physiol. 2012; 227:1326-1334.
41. Vahle JL, Long GG, Sandusky G, Westmore M., Ma YL, Sato M. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol. 2004; 32:426-438.
42. Vahle JL, Sato M, Long G.G., et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002; 30:312-321.
43. Vengellur A, LaPres JJ The role of hypoxia inducible factor 1 α in cobalt chloride induced cell death in mouse embryonic fibroblasts. Toxicol Sci. 2004; 82:638-646.
44. Fox KE, Colton LA, Erickson P.F., et al. Regulation of cyclin D1 and Wnt10b gene expression by cAMP-responsive element-binding protein during early adipogenesis involves differential promoter methylation. J Biol Chem. 2008; 283:35096-35105.
45. Ontiveros C, McCabe LR Simulated microgravity suppresses osteoblast phenotype, Runx2 levels and AP-1 transactivation. J Cell Biochem. 2003; 88:427-437.
46. Ontiveros C, Irwin R, Wiseman R.W., McCabe LR. Hypoxia suppresses runx2 independent of modeled microgravity. J Cell Physiol. 2004; 200:169-176.
47. Li J, Takaishi K, Cook W., McCorkle SK, Unger RH. Insig-1 "brakes" lipogenesis in adipocytes and inhibits differentiation of preadipocytes. Proc Natl Acad Sci USA. 2003; 100:9476-9481.
48. Kast-Woelbern H.R., Dana SL, Cesario R.M., et al. Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor y and sterol regulatory element-binding protein in the regulation of adipogenesis. J Biol Chem. 2004; 279:23908-23915.
49. Li Z, Yang S, Lin H., et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003; 37:343-350.
50. Thomas CM, Hong T, van Pijkeren JP, et al. Histamine derived from probiotic Lactobacillus reuteri suppresses TNF via modulation of PKA and ERK signaling. PLoS One. 7:e31951.
51. Motyl K, McCabe LR Streptozotocin, type I diabetes severity and bone. Biol Proced Online. 2009; 11:296-315.
52. Motyl KJ, Raetz M, Tekalur S.A., Schwartz RC, McCabe LR. CCAAT/enhancer binding protein β-deficiency enhances type 1 diabetic bone phenotype by increasing marrow adiposity and bone resorption. Am J Physiol Regul Integr Comp Physiol. 300:R1250-R1260.
53. Wright WS, Longo KA, Dolinsky V.W., et al. Wnt10b inhibits obesity in ob/ob and agouti mice. Diabetes. 2007; 56:295-303.
54. Seriolo B, Paolino S, Sulli A., Ferretti V, Cutolo M. Bone metabolism changes during anti-TNF-α therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci. 2006; 1069:420-427.
55. Graves DT, Kayal RA Diabetic complications and dysregulated innate immunity. Front Biosci. 2008; 13:1227-1239.
56. Liu R, Bal HS, Desta T, Behl Y., Graves DT. Tumor necrosis factor-α mediates diabetes-enhanced apoptosis of matrix-producing cells and impairs diabetic healing. Am J Pathol. 2006; 168:757-764.
57. Resta-Lenert S., Barrett KE Probiotics and commensals reverse TNF-α- and IFN-7-induced dysfunction in human intestinal epithelial cells. Gastroenterology. 2006; 130:731-746.
58. Mutus R, Kocabagli N, Alp M., Acar N, Eren M, Gezen SS The effect of dietary probiotic supplementation on tibial bone characteristics and strength in broilers. Poult Sci. 2006; 85:1621-1625.
59. Kimoto-Nira H., Suzuki C, Kobayashi M., Sasaki K, Kurisaki J, Mizumachi K. Anti-ageing effect of a lactococcal strain: analysis using senescence-accelerated mice. Br J Nutr. 2007; 98:1178-1186.
60. Ohlsson C, Engdahl C, Fak F., et al. Probiotics protect mice from ovariectomy-induced cortical bone loss. PLoSOne.2014;9:e92368.
61. Stevens JR, Miranda-Carboni GA, Singer M.A., Brugger SM, Lyons KM, Lane TF. Wnt10b deficiency results in age-dependent loss of bone mass and progressive reduction of mesenchymal progenitor cells. J Bone Miner Res. 25:2138-2147.
62. Kennell JA, MacDougald OA Wnt signaling inhibits adipogenesis through β-catenin-dependent and - independent mechanisms. J Biol Chem. 2005; 280:24004-24010.
63. Longo KA, Wright WS, Kang S, et al Wnt10b inhibits development of white and brown adipose tissues. J Biol Chem. 2004; 279:35503-35509.
64. Zhou FH, Foster BK, Zhou X.F., Cowin AJ, Xian CJ. TNF-α mediates p38 MAP kinase activation and negatively regulates bone formation at the injured growth plate in rats. J Bone Miner Res. 2006; 21: 1075-1088.
65. Boyce BF, Li P, Yao Z., et al. TNF-α and pathologic bone resorption. Keio J Med. 2005; 54:127-131.
66. Saidenberg-Kermanac'h N, Corrado A, Lemeiter D, deVernejoul MC, Boissier MC, Cohen-Solal ME. TNF-α antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone. 2004; 35:1200-1207.
67. Miheller P, Muzes G, Zagoni T., Toth M, Racz K, Tulassay Z. Infliximab therapy improves the bone metabolism in fistulizing Crohn's disease. Dig Dis. 2006; 24:201-206.
68. Pazianas M, Rhim AD, Weinberg A.M., Su C., Lichtenstein GR. The effect of anti-TNF-α therapy on spinal bone mineral density in patients with Crohn's disease. Ann NY Acad Sci. 2006; 1068:543-556.
69. Uno JK, Kolek OI, Hines E.R., et al. The role of tumor necrosis factor α in down-regulation of osteoblast Phex gene expression in experimental murine colitis. Gastroenterology. 2006; 131:497-509.
70. Durnez A, Paternotte S, Fechtenbaum J., et al. Increase in bone density in patients with spondyloarthritis during anti-tumor necrosis factor therapy: 6-year followup study. J Rheumatol. 2013; 40:1712-1718.
71. Li Y, Li A, Strait K., Zhang H, Nanes MS, Weitzmann MN Endogenous TNFα lowers maximum peak bone mass and inhibits osteoblastic Smad activation through NF-ΚB. J Bone Miner Res. 2007; 22:646-655.
72. Iyer C, Kosters A, Sethi G., Kunnumakkara AB, Aggarwal BB, Versalovic J. Probiotic Lactobacillus reuteri promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-ΚB and MAPK signalling. Cell Microbiol. 2008; 10:1442-1452.
73. Pacifici R. Role of T cells in ovariectomy induced bone loss-revisited. J Bone Miner Res. 2012; 27:231-239.
74. Robinson JW, Li JY, Walker L.D., et al. T cell-expressed CD40L potentiates the bone anabolic activity of intermittent PTH treatment. J Bone Miner Res. 2015; 30:695-705.
75. Riddle RC, Diegel CR, Leslie J.M., et al. Lrp5 and Lrp6 exert overlapping functions in osteoblasts during postnatal bone acquisition. PLoS One. 2013; 8:e63323.